GSK is enlisting the aid of China’s Chongqing Zhifei Biological Products (Zhifei) to drive sales of its most important vaccine, Shingrix, in China over the next few years, and may also call upon ...

GlaxoSmithKline places its shingles vaccine Shingrix among its top prospects, with peak sales potential of almost $6 billion. Now, Pfizer and BioNTech are joining forces to try to grab a slice of ...

GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

GlaxoSmithKline Pharmaceuticals Ltd (GSK) on Friday announced its financial results for the third quarter ended December 31, 2024. According to the company’s exchange filing, it demonstrates ...

GlaxoSmithKline Pharmaceuticals Limited is ... In 2022-23, the Company launched Shingrix, a vaccine for prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) in adults who are 50 ...

Bengaluru: India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by ...

"The adult vaccines division continues to gain momentum with Shingrix (herpes zoster vaccine—recombinant, adjuvanted), as GSK Pharma spearheads the expansion of adult immunisation in India," the ...

GlaxoSmithKline Pharma has been benefitting from rising market share for its antibiotic Augmentin and respiratory drugs Nucala and Trelegy. Strong demand for its vaccine for shingles, Shingrix, has ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...